drugset

drugset / Trial / NCT01920854

A Single Ascending Dose Study of Soluble Ferric Pyrophosphate Administered Intravenously in Healthy Volunteers.

NCT01920854 ↗

Phase 1 Completed 48 enrolled Rockwell Medical Technologies, Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine the pharmacokinetics of fixed ascending doses of intravenously administered Soluble Ferric Pyrophosphate

Timeline

Start: 2013-06
Primary completion: 2013-09
Completion: 2013-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Triferic	Other / unclassified	—	Intravenous

Indications